Besides ADC, which are probably the most promising nanomedicines, other active targeted nanosystems have reached the clinic for the treatment of BC including Abraxane® and Nab-rapamicyn (albumin nanoparticles entrapping rapamycin) and various liposomes (MM-302, C225-ILS-Dox, and MM-310) loaded with doxorubicin or docetaxel and coated with ligands targeting HER-2 and other receptors, such as Ephrin 2. Here, ALB is linked to breast cancer.